Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Wonder

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|May 14, 2014
What can be gained from increased early-stage interaction between regulators, payers and the pharmaceutical industry?Michael Wonder
Value in Health Regional Issues|November 25, 2016
Registration and Reimbursement of New Cancer Medicines in AustraliaMichael Wonder
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 22, 2012
Patient access to new cancer drugs in the United States and AustraliaMichael Wonder
Australian Health Review : a Publication of the Australian Hospital Association|March 10, 2015
Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New ZealandColman Taylor, Michael Wonder
Health Policy (Amsterdam, Netherlands)|February 25, 2014
Is there any evidence that the Trans Pacific Partnership Agreement will threaten access to affordable medicines and health equity in New Zealand?Michael Wonder, Richard Milne
International Journal of Technology Assessment in Health Care|June 12, 2020
Analysis of PBAC submissions and outcomes for medicines (2010-2018)Sean Lybrand, Michael Wonder
Expert Review of Pharmacoeconomics & Outcomes Research|May 5, 2015
What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012)Michael Wonder, Geoffrey Chin
Australian Health Review : a Publication of the Australian Hospital Association|July 2, 2013
Delays in access to affordable medicines: putting policy into perspectiveMichael Wonder, Geoffrey Chin
Pharmacoeconomics|January 19, 2013
Comparing subsidized access to medicines across payer systemsMichael Wonder, Richard Milne
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 21, 2015
Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?Michael Wonder, Sheryl Dunlop
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Expert Review of Pharmacoeconomics & Outcomes Research|May 14, 2014
What can be gained from increased early-stage interaction between regulators, payers and the pharmaceutical industry?Michael Wonder
Value in Health Regional Issues|November 25, 2016
Registration and Reimbursement of New Cancer Medicines in AustraliaMichael Wonder
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 22, 2012
Patient access to new cancer drugs in the United States and AustraliaMichael Wonder
Australian Health Review : a Publication of the Australian Hospital Association|March 10, 2015
Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New ZealandColman Taylor, Michael Wonder
Health Policy (Amsterdam, Netherlands)|February 25, 2014
Is there any evidence that the Trans Pacific Partnership Agreement will threaten access to affordable medicines and health equity in New Zealand?Michael Wonder, Richard Milne
International Journal of Technology Assessment in Health Care|June 12, 2020
Analysis of PBAC submissions and outcomes for medicines (2010-2018)Sean Lybrand, Michael Wonder
Expert Review of Pharmacoeconomics & Outcomes Research|May 5, 2015
What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012)Michael Wonder, Geoffrey Chin
Australian Health Review : a Publication of the Australian Hospital Association|July 2, 2013
Delays in access to affordable medicines: putting policy into perspectiveMichael Wonder, Geoffrey Chin
Pharmacoeconomics|January 19, 2013
Comparing subsidized access to medicines across payer systemsMichael Wonder, Richard Milne
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 21, 2015
Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?Michael Wonder, Sheryl Dunlop
Pageof 3